Glivec in Prostate Cancer Patients With Rising PSA Following Radical Prostectomy
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
To investigate the ability of 600 mg of Glivec®, given once daily by mouth to patients with
rising PSA following radical prostatectomy, to produce a sustained biochemical response
during the first 6 months of treatment.